Filter
119
Filtered Results: 119
Text search:
ICMR
Indian
Council
of
Medical
Research
Featured
Recommendations
5
New Publications
37
Language
Document type
No document type
91
Guidelines
16
Studies & Reports
6
Fact sheets
3
Manuals
1
Resource Platforms
1
Strategic & Response Plan
1
Countries / Regions
India
104
Global
3
Asia
2
Nepal
1
Peru
1
South–East Asia Region
1
Authors & Publishers
Publication Years
Category
Countries
100
Clinical Guidelines
5
Public Health
3
Key Resources
1
Pharmacy & Technologies
1
Toolboxes
COVID-19
7
AMR
5
TB
3
Mental Health
2
Specific Hazards
2
Caregiver
2
Planetary Health
2
NTDs
2
NCDs
2
Rapid Response
1
Zika
1
Health Financing Toolbox
1
Prepared as an outcome of ICMR Subcommittee on Multiple Myeloma | This consensus document on management of multiple myeloma summarizes the modaliti...
Prepared as an outcome of ICMR Subcommittee on Non Hodgkin’s Lymphoma (High Grade) | This consensus document on management of non- hodgkin’s l...
Prepared as an outcome of ICMR Subcommittee on Soft Tissue Sarcoma and Osteosarcoma | This consensus document on Management of Soft Tissue Sarcoma...
Prepared as an outcome of ICMR Expert Group on Immunophenotyping of Hematolymphoid Neoplasms | Coordinated by Division ... Non Communicable Diseases | This document addresses on various issue related to good quality practices in laboratory work up of flow cytometric immunophenotyping and will be of use to pathologists, cytometrists, hematologists, technologists and scientists working in this field.
These guidelines are applicable to all biomedical, social and behavioural science research for health conducted in India involving human participants, their biological material and data.
The purpose of...
These Guidelines are intended to provide knowledge to the treating ophthalmologists, pediatricians, ocular oncologists, pediatric oncologists, and general physicians to arrive at an early diagnosis of retinoblastoma in the settings ... district hospital, in private clinics and hospitals. The guidelines will enable the contact health personnel to refer at the right
time to the tertiary care hospital for management of retinoblastoma.
The ICMR type 1 diabetes guidelines come at a time when the SARS-CoV-2 pandemic
has disproportionately affected people with diabetes population, exposing them to a
high risk for severe illness and mortality. Globally, diabetes was responsible for ...
Prepared as an outcome of ICMR Subcommittee on Colorectal Cancer | Coordinated by Division of Non Communicable Diseases | This Consensus Document o...
Page visited January 2019, publication date unknown.
The main objective of these guidelines is to provide guidance on up-to-date, uniform, evidence-informed practices for suspecting, diagnosing and managing various forms of extra-pulmonary tuberculosi...
Guidelines for Good Clinical Laboratory Practices (GCLP) outlines the principles and procedures to be followed by medical laboratories involved in clinical research and/or patient care so as to prov...
Accessed online January 2019, date of publication unknown.
The publication of the of the Antimicrobial Treatment Guidelines represents the
culmination of the efforts ... the Antimicrobial Stewardship Program of ICMR to publish treatment guidelines for common syndromes in India. These guidelines are targeted for the health care settings. It aims to rationalize the usage of antibiotics on our Essential Medicines Formulary (EMF) and to establish consistency in the treatment of various infectious conditions.
SOP number: ICMR-NIV/2019-nCoV/Specimens_01
Prepared by: Dr. Y.K. Gurav Reviewed by: Dr. V. Potdar Approved by: Dr. P. Abraham
Date: 19/01/2020 Date: 20/01/2020 Date: 20/01/2020
Republic of India (hereinafter the Recipient) willimplement the Covid-19 Emergency Response and Health Systems Preparedness project (the Project), with the involvement of the following Ministries/Ag...
COVAXINTM, India's indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of ... Research (ICMR) - National Institute of Virology (NIV). The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) high containment facility.
The vaccine received DCGI approval for Phase I & II Human Clinical Trials and the trials commenced across India from July, 2020.
After successful completion of the interim analysis from the Phase 1 & 2 clinical trials of COVAXINTM, Bharat Biotech received DCGI approval for Phase 3 clinical trials in 26,000 participants in over 25 centres across India.
Accessed January 2019, publication date unknown.
The guidelines reiterate that the general principles of ethics for biomedical research involving human participants shall also be applicable. In addition, the guidelines specify unique provisions fo...
